-
AI-10-49: A CBFβ-SMMHC Assay Strategy
2026-08-24
AI-10-49 is a selective CBFβ-SMMHC inhibitor for dissecting fusion-driven leukemia biology. This article presents a causal, multi-readout assay strategy linking RUNX1 restoration to MYCN/eIF4G1-dependent survival in inv(16) AML.
-
Tamoxifen at the Neuro-Immune Interface
2026-08-23
Tamoxifen is more than a selective estrogen receptor modulator or CreER trigger. Its receptor pharmacology, chaperone activity, and potential immunological confounding make it a strategic variable in translational models. This article connects Tamoxifen-enabled conditional genetics with a recent study defining how myeloid TET2, neuronal IL-1R signaling, catecholamines, enterochromaffin cells, and serotonin shape intestinal inflammation.
-
Machine Learning Predicts LNPs for mRNA Vaccines
2026-08-22
Wang and colleagues developed a LightGBM model to predict the performance of lipid nanoparticles used in mRNA vaccines and identified ionizable-lipid substructures associated with activity. Experimental comparison of MC3 and SM-102, together with molecular dynamics modeling, showed how computational prediction can guide formulation selection while highlighting the limits of translating model results across delivery systems.
-
HyperPFU™ high-fidelity DNA polymerase guide
2026-08-21
HyperPFU™ high-fidelity DNA polymerase is intended for accurate PCR amplification of long, GC-rich, or otherwise difficult DNA templates, with proofreading activity and blunt-ended products. It is suitable for cloning and sequencing workflows but should not be selected when the protocol requires 3′-A overhangs or sticky-end generation.
-
U 46619: TP Signaling Across Platelet and Kidney Models
2026-08-20
U 46619, also known as 11,9 epoxymethano-prostaglandin H2, provides a controlled TP-receptor challenge for platelet and vascular experiments. This article connects its concentration-dependent responses with renal ischemia-reperfusion research while defining what the current evidence does—and does not—support.
-
Thrombin B Chain Fragment: Assay Design Guide
2026-08-20
Explore how the Thrombin B Chain Fragment [Homo sapiens] can support sequence-defined protease and coagulation research. This guide connects product selection with kinetic assay design, orthogonal controls, and lessons from selective protease-inhibitor screening.
-
ML133 HCl: Kir2.1 Inhibition in PASMC Research
2026-08-19
ML133 HCl is a selective potassium channel inhibitor for connecting Kir2.1 activity with pulmonary artery smooth muscle cell proliferation, migration, and vascular remodeling. This practical guide translates reference-study findings into dose planning, assay workflows, controls, and troubleshooting for cardiovascular ion channel research.
-
EdU Imaging Kits (Cy5) for S-Phase Research
2026-08-19
EdU Imaging Kits (Cy5) convert DNA replication into a sensitive Cy5 readout for morphology-preserving microscopy and quantitative flow cytometry. This workflow is especially useful for testing how tadalafil-conditioned MSC exosomes affect pulmonary vascular cell proliferation, while also supporting genotoxicity and pharmacodynamic studies.
-
Instant Clot-Forming Dressings with TXA, NO, and Propolis
2026-08-18
This 2024 study introduces a bi-layer wound dressing that combines Tranexamic Acid, the nitric oxide donor SNAP, and propolis to address hemorrhage and bacterial contamination in trauma wounds. The formulation promoted early fibrin activation, produced a dense fibrin network, and substantially reduced bacterial colony counts in vitro, while also highlighting the experimental limits of translating composite-dressing data to clinical trauma care.
-
Naftifine HCl: Antifungal Assay Workflows
2026-08-18
Build reproducible dermatophyte assays with Naftifine HCl by controlling solvent, exposure, inoculum, and orthogonal readouts. The workflow connects its ergosterol-focused mechanism with the multiparameter assay logic used in modern cell-biology studies, without conflating antifungal evidence with muscle-regeneration biology.
-
Fluo-4 AM Calcium Assay Kit for Mechanotransduction
2026-08-17
The Fluo-4 AM Calcium Assay Kit converts scaffold-driven calcium flux into a practical live-cell readout for annulus fibrosus mechanobiology. Its 488 nm-compatible, no-wash workflow also supports scalable GPCR inhibitor screening and GPCR agonist screening while preserving cells for downstream phenotype analysis.
-
NF 449 and Platelet P2X1: Evidence from a 2005 Study
2026-08-17
Hechler and colleagues established NF 449 as a functionally selective antagonist of platelet P2X1, distinguishing ATP-gated signaling from P2Y1- and P2Y12-mediated responses. Their human platelet and mouse thrombosis experiments linked P2X1 blockade to reduced collagen-triggered activation and thrombus formation, while also showing that selectivity depends on dose.
-
Ambroxol Targets Nav1.8, TRPV1, and TRPA1
2026-08-16
A 2025 Journal of Pain study used whole-cell patch-clamp recordings to define how ambroxol modulates human and rat Nav1.8, TRPV1, and TRPA1 channels. Its central contribution is the demonstration of pronounced species dependence at Nav1.8 and additional, concentration-dependent effects on human irritant receptors relevant to topical neuropathic pain.
-
Sex Differences in Angiotensin II Hypertension
2026-08-15
Xue, Pamidimukkala, and Hay used radiotelemetry in conscious mice to show that chronic angiotensin II produces a substantially larger blood-pressure increase in males than females. Gonadectomy, baroreflex testing, and ganglionic blockade linked this divergence to sex-dependent hormonal and sympathetic regulation, providing a framework for studying sex as a biological variable in hypertension.
-
Merbromin as a Mixed-Type 3CLpro Inhibitor
2026-08-14
A high-throughput screen of approximately 6,000 compounds identified merbromin as a selective inhibitor of the SARS-CoV-2 main protease, 3CLpro. Enzyme kinetics, binding analysis, and molecular docking supported a mixed-type inhibition model and provided a framework for developing and validating antiviral protease inhibitors.